Menu Search
Equities

XOMA Royalty Corp

XOMA:NMQ

XOMA Royalty Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)30.97
  • Today's Change0.77 / 2.55%
  • Shares traded23.67k
  • 1 Year change+102.95%
  • Beta0.8628
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year XOMA Royalty Corp's revenues fell -21.06% from 6.03m to 4.76m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 17.10m to a larger loss of 40.83m.
Gross margin--
Net profit margin-119.61%
Operating margin-154.13%
Return on assets-9.88%
Return on equity-23.90%
Return on investment-10.62%
More ▼

Cash flow in USDView more

In 2023, XOMA Royalty Corp increased its cash reserves by 175.91%, or 101.72m. Cash Flow from Financing totalled 120.59m or 2,534.53% of revenues. In addition the company used 18.16m for operations while cash used for investing totalled 711.00k.
Cash flow per share-1.79
Price/Cash flow per share--
Book value per share8.58
Tangible book value per share8.58
More ▼

Balance sheet in USDView more

XOMA Royalty Corp appears to have a strong balance sheet and has grown its cash reserves consistently over the last four years to total 153.29m. In fact, 0.42% of the value of XOMA Royalty Corp shares can be attributed to this cash.
Current ratio8.71
Quick ratio--
Total debt/total equity1.21
Total debt/total capital0.5471
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.